SCHEMBL2548596

SCHEMBL2548596

CCCCCOc1ccc(CCCCC)cc1CC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
NPC1 O15118 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
ALDH1A1 P00352 3/20 0.56
MAPT P10636 3/20 0.55
THRB P10828 3/20 0.55
MAPK1 P28482 2/20 0.55
APAF1 O14727 2/20 0.55
PTPN11 Q06124 2/20 0.55
PTPN1 P18031 1/20 0.55
PTPN6 P29350 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
RAD52 P43351 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
PLA2G2D Q9UNK4 1/20 0.52
HPGD P15428 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2542877 0.88 LTB4R (0.62) HTTMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL27452473 0.85 ALDH1A1 (0.55) ALDH1A1PTPN11PTPN1PTPN6HPGD
SCHEMBL7813434 0.85 HTT (0.60) HTTMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL28381703 0.84 HTT (0.59) HTTMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL11522071 0.82 HTT (0.69) HTTMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL8166807 0.82 TSHR (0.61) HTTMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL5696303 0.81 TSHR (0.64) HTTMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL9250002 0.80 PTPN11 (0.64) HTTMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL8681872 0.80 HTT (0.54) HTTMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL290939 0.80 ALDH1A1 (0.63) ALDH1A1HPGDHSD17B10PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044236-B2 Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-10-25 US disclosed
EP-2080751-A1 CARBOXYLIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-07-22 EP disclosed
US-20080275116-A1 Carboxilic acid derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275116-A1 Carboxilic acid derivatives SERPINE1, CTRL, SERPINC1 HTT 3043/4885MEN1 903/4885KMT2A 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.